Biotech | March 16, 2022
Wockhardt’s novel antibiotic Phase 1 trial to be conducted by NIH, USA
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
